US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

登録

ホーム
投資
株式
アメリカ
NASDAQ
Poseida Therapeutics Inc (PSTX)
Poseida Therapeutics Inc (PSTX) ニュース

PSTX

Poseida Therapeutics (PSTX)

Poseida Therapeutics Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:PSTX

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/09/16	21 : 00	PR Newswire (US)	Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for P-BCMA-ALLO1 to Treat Relapsed/Refractory Multiple Myeloma	NASDAQ:PSTX	Poseida Therapeutics Inc
2024/09/05	22 : 00	PR Newswire (US)	Poseida Therapeutics to Present New Clinical Data from Phase 1 Study of Allogeneic CAR-T P-BCMA-ALLO1 in Patients with Relapsed/Refractory Multiple Myeloma at 21st International Myeloma Society Annual Meeting	NASDAQ:PSTX	Poseida Therapeutics Inc
2024/09/05	05 : 05	PR Newswire (US)	Poseida Therapeutics Presents New Case Study Demonstrating Reactivation of CAR-T Therapy with a T-Cell Engager in a Patient with Relapsed Multiple Myeloma	NASDAQ:PSTX	Poseida Therapeutics Inc
2024/08/30	05 : 05	PR Newswire (US)	Poseida Therapeutics to Present at Upcoming Investor Conferences	NASDAQ:PSTX	Poseida Therapeutics Inc
2024/08/15	13 : 15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:PSTX	Poseida Therapeutics Inc
2024/08/06	05 : 33	Edgar (US Regulatory)	Form S-3 - Registration statement under Securities Act of 1933	NASDAQ:PSTX	Poseida Therapeutics Inc
2024/08/06	05 : 10	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:PSTX	Poseida Therapeutics Inc
2024/08/06	05 : 05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:PSTX	Poseida Therapeutics Inc
2024/08/06	05 : 05	PR Newswire (US)	Poseida Therapeutics Provides Updates and Financial Results for the Second Quarter of 2024	NASDAQ:PSTX	Poseida Therapeutics Inc
2024/07/02	05 : 05	PR Newswire (US)	Poseida Therapeutics Announces Participation in Stifel's 2024 Virtual Cell Therapy Forum	NASDAQ:PSTX	Poseida Therapeutics Inc
2024/06/19	05 : 15	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:PSTX	Poseida Therapeutics Inc
2024/06/19	05 : 12	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:PSTX	Poseida Therapeutics Inc
2024/06/19	05 : 10	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:PSTX	Poseida Therapeutics Inc
2024/06/04	05 : 05	PR Newswire (US)	Poseida Therapeutics Announces Virtual 2024 Annual Meeting of Stockholders	NASDAQ:PSTX	Poseida Therapeutics Inc
2024/05/15	05 : 11	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:PSTX	Poseida Therapeutics Inc
2024/05/15	05 : 06	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:PSTX	Poseida Therapeutics Inc
2024/05/15	05 : 05	PR Newswire (US)	Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024	NASDAQ:PSTX	Poseida Therapeutics Inc
2024/05/09	22 : 00	PR Newswire (US)	Poseida Highlights Strong Progress on Its Genetic Medicine Programs at the American Society for Gene and Cell Therapy 27th Annual Meeting	NASDAQ:PSTX	Poseida Therapeutics Inc
2024/05/06	13 : 15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:PSTX	Poseida Therapeutics Inc
2024/05/02	10 : 30	PR Newswire (US)	Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology	NASDAQ:PSTX	Poseida Therapeutics Inc
2024/05/02	04 : 25	AllPennyStocks.com	Biotech Soars on Research Collaboration And License Agreement Release	NASDAQ:PSTX	Poseida Therapeutics Inc
2024/05/01	22 : 00	PR Newswire (US)	Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology	NASDAQ:PSTX	Poseida Therapeutics Inc
2024/04/18	21 : 00	PR Newswire (US)	Poseida Therapeutics Announces Strong Lineup of Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting	NASDAQ:PSTX	Poseida Therapeutics Inc
2024/04/17	22 : 00	PR Newswire (US)	Poseida Therapeutics Hosts Gene Therapy R&D Day Highlighting New Scientific Advancements and Pipeline Focus	NASDAQ:PSTX	Poseida Therapeutics Inc
2024/04/09	01 : 00	PR Newswire (US)	Poseida Therapeutics Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-ALLO1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma	NASDAQ:PSTX	Poseida Therapeutics Inc
2024/04/02	05 : 05	PR Newswire (US)	Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:PSTX	Poseida Therapeutics Inc
2024/03/26	05 : 05	PR Newswire (US)	Poseida Therapeutics Appoints Syed Rizvi, M.D., as Chief Medical Officer	NASDAQ:PSTX	Poseida Therapeutics Inc
2024/03/20	05 : 05	PR Newswire (US)	Poseida Therapeutics to Present at H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference	NASDAQ:PSTX	Poseida Therapeutics Inc
2024/03/14	05 : 05	PR Newswire (US)	Poseida Therapeutics Announces FDA Orphan Drug Designation Granted to P-BCMA-ALLO1 for the Treatment of Multiple Myeloma	NASDAQ:PSTX	Poseida Therapeutics Inc
2024/03/08	06 : 07	PR Newswire (US)	Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2023	NASDAQ:PSTX	Poseida Therapeutics Inc

Showing the most relevant articles for your search:NASDAQ:PSTX

1 2 3 4 5 6 7 8 9 10 次へ >>

Paris Saint-Germain

Alibaba 3xs �

BlackRock Asset Manageme...

BNP Paribas Issuance

China Health Industries (QB)

WisdomTree Issuer ICAV

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約